(STOK) Stoke Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86150R1077

STK-002,Zorevunersen,ASOs,TANGO,Genetic

STOK EPS (Earnings per Share)

EPS (Earnings per Share) of STOK over the last years for every Quarter: "2020-09": -0.41, "2020-12": -0.42, "2021-03": -0.46, "2021-06": -0.6, "2021-09": -0.61, "2021-12": -0.66, "2022-03": -0.66, "2022-06": -0.63, "2022-09": -0.66, "2022-12": -0.65, "2023-03": -0.53, "2023-06": -0.69, "2023-09": -0.55, "2023-12": -0.6, "2024-03": -0.57, "2024-06": -0.46, "2024-09": -0.4691, "2024-12": -0.18, "2025-03": 1.9, "2025-06": -0.4, "2025-09": 0,

STOK Revenue

Revenue of STOK over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 3, 2022-06: 3.231, 2022-09: 2.905, 2022-12: 3.269, 2023-03: 5.152, 2023-06: -2.481, 2023-09: 3.308, 2023-12: 2.802, 2024-03: 4.216, 2024-06: 4.831, 2024-09: 4.894, 2024-12: 22.614, 2025-03: 158.569, 2025-06: 13.817, 2025-09: null,

Description: STOK Stoke Therapeutics

Stoke Therapeutics (NASDAQ: STOK) is an early‑stage biotech focused on treating severe genetic disorders by boosting endogenous protein production through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) antisense oligonucleotide (ASO) platform.

The company’s pipeline centers on two lead candidates. STK‑001 (zorevunersen) is an ASO designed to increase SCN1A expression for Dravet syndrome, a rare pediatric epilepsy with an estimated U.S. prevalence of ~1,200 patients. The program is currently in a combined Phase I/II trial, with Biogen providing development and commercial partnership support—including an upfront cash payment (reported in the 2023 Form 10‑K as $15 M) and potential milestone payments that could exceed $300 M if regulatory and sales targets are met.

STK‑002 targets autosomal dominant optic atrophy (ADOA), a hereditary optic neuropathy affecting roughly 1 in 50,000 individuals worldwide. The asset remains in pre‑clinical development, and Stoke is pursuing additional collaborations to fund later‑stage studies. If successful, ADOA could represent a niche market of ~15,000 patients globally, translating to a potential addressable revenue of $150 M–$300 M assuming a $10,000‑$20,000 annual therapy price.

Stoke’s broader R&D agenda includes multiple haploinsufficiency programs for central‑nervous‑system and ocular diseases, leveraging the TANGO platform’s ability to up‑regulate any target gene with a suitable ASO design. This platform‑centric approach creates a scalable asset pipeline, but also concentrates risk on the clinical validation of a single technology class.

Key economic drivers for Stoke include: (1) the size and pricing power of rare‑disease markets, where orphan‑drug premiums can support annual list prices above $100,000; (2) the depth of its strategic alliances—Biogen provides not only capital but also regulatory expertise and a potential commercial launch engine, while Acadia offers co‑development capabilities for neurodevelopmental indications; and (3) the company’s cash runway, which, based on the most recent quarterly filing, stood at roughly $30 M, sufficient for 12–18 months of R&D spend assuming current burn rates (~$15 M‑$20 M per year).

Critical uncertainties remain. First, ASO therapies historically face a high attrition rate (≈70 % failure before Phase III), especially for central‑nervous‑system delivery. Second, regulatory pathways for gene‑expression augmentation are still evolving, potentially extending time‑to‑market. Third, competition from alternative modalities (e.g., gene‑replacement viral vectors, CRISPR‑based editing) could erode market share if they achieve comparable efficacy with fewer dosing requirements.

From a valuation perspective, Stoke’s market capitalization (≈$150 M‑$200 M as of Q2 2025) reflects a high‑risk, high‑reward profile. The upside hinges on successful Phase II read‑outs for STK‑001 and the de‑risking of the TANGO platform through additional IND filings. Conversely, failure to demonstrate meaningful clinical benefit in Dravet syndrome would likely precipitate a steep re‑rating, given the company’s limited diversification beyond its two primary candidates.

STOK Stock Overview

Market Cap in USD 1,671m
Sub-Industry Biotechnology
IPO / Inception 2019-06-19

STOK Stock Ratings

Growth Rating 38.8%
Fundamental 79.4%
Dividend Rating -
Return 12m vs S&P 500 139%
Analyst Rating 4.60 of 5

STOK Dividends

Currently no dividends paid

STOK Growth Ratios

Growth Correlation 3m 96.4%
Growth Correlation 12m 36.9%
Growth Correlation 5y -61.4%
CAGR 5y 39.18%
CAGR/Max DD 3y (Calmar Ratio) 0.50
CAGR/Mean DD 3y (Pain Ratio) 1.01
Sharpe Ratio 12m 1.24
Alpha 187.18
Beta 1.244
Volatility 72.54%
Current Volume 1899.5k
Average Volume 20d 1019k
Stop Loss 33.1 (-5.3%)
Signal 2.83

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (52.5m TTM) > 0 and > 6% of Revenue (6% = 12.0m TTM)
FCFTA 0.16 (>2.0%) and ΔFCFTA 42.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 115.7% (prev 1666 %; Δ -1550 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.16 (>3.0%) and CFO 61.6m > Net Income 52.5m (YES >=105%, WARN >=100%)
Net Debt (-99.2m) to EBITDA (42.3m) ratio: -2.35 <= 3.0 (WARN <= 3.5)
Current Ratio 6.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (58.4m) change vs 12m ago 4.64% (target <= -2.0% for YES)
Gross Margin 98.35% (prev 69.40%; Δ 28.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 57.75% (prev 4.92%; Δ 52.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 3.94 (EBITDA TTM 42.3m / Interest Expense TTM 10.2m) >= 6 (WARN >= 3)

Altman Z'' -7.18

(A) 0.60 = (Total Current Assets 270.0m - Total Current Liabilities 38.7m) / Total Assets 384.5m
(B) -1.04 = Retained Earnings (Balance) -401.4m / Total Assets 384.5m
warn (B) unusual magnitude: -1.04 — check mapping/units
(C) 0.12 = EBIT TTM 40.3m / Avg Total Assets 346.1m
(D) -8.10 = Book Value of Equity -401.3m / Total Liabilities 49.6m
Total Rating: -7.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.35

1. Piotroski 6.50pt = 1.50
2. FCF Yield 4.29% = 2.14
3. FCF Margin 30.59% = 7.50
4. Debt/Equity 0.01 = 2.50
5. Debt/Ebitda -2.35 = 2.50
6. ROIC - WACC (= 3.47)% = 4.34
7. RoE 18.32% = 1.53
8. Rev. Trend 61.65% = 4.62
9. EPS Trend 54.37% = 2.72

What is the price of STOK shares?

As of October 16, 2025, the stock is trading at USD 34.94 with a total of 1,899,536 shares traded.
Over the past week, the price has changed by +27.94%, over one month by +49.32%, over three months by +189.72% and over the past year by +173.82%.

Is Stoke Therapeutics a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Stoke Therapeutics (NASDAQ:STOK) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 79.35 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STOK is around 30.66 USD . This means that STOK is currently overvalued and has a potential downside of -12.25%.

Is STOK a buy, sell or hold?

Stoke Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy STOK.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the STOK price?

Issuer Target Up/Down from current
Wallstreet Target Price 25.6 -26.8%
Analysts Target Price 25.6 -26.8%
ValueRay Target Price 34.8 -0.3%

Last update: 2025-10-10 03:54

STOK Fundamental Data Overview

Market Cap USD = 1.67b (1.67b USD * 1.0 USD.USD)
P/E Trailing = 35.0575
P/E Forward = 204.0816
P/S = 8.3611
P/B = 4.0606
Beta = 1.244
Revenue TTM = 199.9m USD
EBIT TTM = 40.3m USD
EBITDA TTM = 42.3m USD
Long Term Debt = 2.30m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 2.30m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -99.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.43b USD (1.67b + Debt 2.30m - CCE 247.7m)
Interest Coverage Ratio = 3.94 (Ebit TTM 40.3m / Interest Expense TTM 10.2m)
FCF Yield = 4.29% (FCF TTM 61.1m / Enterprise Value 1.43b)
FCF Margin = 30.59% (FCF TTM 61.1m / Revenue TTM 199.9m)
Net Margin = 26.26% (Net Income TTM 52.5m / Revenue TTM 199.9m)
Gross Margin = 98.35% ((Revenue TTM 199.9m - Cost of Revenue TTM 3.29m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 99.32%)
Tobins Q-Ratio = 3.71 (Enterprise Value 1.43b / Total Assets 384.5m)
Interest Expense / Debt = 165.0% (Interest Expense 3.79m / Debt 2.30m)
Taxrate = -0.0% (0.0 / -23.5m)
NOPAT = 40.3m (EBIT 40.3m * (1 - -0.00%))
Current Ratio = 6.98 (Total Current Assets 270.0m / Total Current Liabilities 38.7m)
Debt / Equity = 0.01 (Debt 2.30m / totalStockholderEquity, last quarter 334.9m)
Debt / EBITDA = -2.35 (Net Debt -99.2m / EBITDA 42.3m)
Debt / FCF = -1.62 (Net Debt -99.2m / FCF TTM 61.1m)
Total Stockholder Equity = 286.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.65% (Net Income 52.5m / Total Assets 384.5m)
RoE = 18.32% (Net Income TTM 52.5m / Total Stockholder Equity 286.5m)
RoCE = 13.95% (EBIT 40.3m / Capital Employed (Equity 286.5m + L.T.Debt 2.30m))
RoIC = 14.06% (NOPAT 40.3m / Invested Capital 286.5m)
WACC = 10.59% (E(1.67b)/V(1.67b) * Re(10.60%) + (debt cost/tax rate unavailable))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.93%
[DCF Debug] Terminal Value 69.31% ; FCFE base≈61.1m ; Y1≈60.5m ; Y5≈63.0m
Fair Price DCF = 13.58 (DCF Value 743.9m / Shares Outstanding 54.8m; 5y FCF grow -1.77% → 3.0% )
EPS Correlation: 54.37 | EPS CAGR: 112.2% | SUE: 0.86 | # QB: 1
Revenue Correlation: 61.65 | Revenue CAGR: 76.31% | SUE: 0.19 | # QB: 0

Additional Sources for STOK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle